The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilars Treatment Market Research Report 2025
Synopsis
The global Biosimilars Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Treatment.
Report Scope
The Biosimilars Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Segment by Type
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Segment by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Biosimilars Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Treatment.
Report Scope
The Biosimilars Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Segment by Type
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Segment by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Recombinant Non – Glycosylated Proteins
1.2.3 Recombinant Glycosylated Proteins
1.2.4 Recombinant Peptides
1.3 Market by Application
1.3.1 Global Biosimilars Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Chronic and Autoimmune Disease
1.3.4 Blood Disorders
1.3.5 Growth Hormone Disease
1.3.6 Infectious Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars Treatment Market Perspective (2019-2030)
2.2 Biosimilars Treatment Growth Trends by Region
2.2.1 Global Biosimilars Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilars Treatment Historic Market Size by Region (2019-2024)
2.2.3 Biosimilars Treatment Forecasted Market Size by Region (2025-2030)
2.3 Biosimilars Treatment Market Dynamics
2.3.1 Biosimilars Treatment Industry Trends
2.3.2 Biosimilars Treatment Market Drivers
2.3.3 Biosimilars Treatment Market Challenges
2.3.4 Biosimilars Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars Treatment Players by Revenue
3.1.1 Global Top Biosimilars Treatment Players by Revenue (2019-2024)
3.1.2 Global Biosimilars Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilars Treatment Revenue
3.4 Global Biosimilars Treatment Market Concentration Ratio
3.4.1 Global Biosimilars Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars Treatment Revenue in 2023
3.5 Biosimilars Treatment Key Players Head office and Area Served
3.6 Key Players Biosimilars Treatment Product Solution and Service
3.7 Date of Enter into Biosimilars Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilars Treatment Breakdown Data by Type
4.1 Global Biosimilars Treatment Historic Market Size by Type (2019-2024)
4.2 Global Biosimilars Treatment Forecasted Market Size by Type (2025-2030)
5 Biosimilars Treatment Breakdown Data by Application
5.1 Global Biosimilars Treatment Historic Market Size by Application (2019-2024)
5.2 Global Biosimilars Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilars Treatment Market Size (2019-2030)
6.2 North America Biosimilars Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilars Treatment Market Size by Country (2019-2024)
6.4 North America Biosimilars Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars Treatment Market Size (2019-2030)
7.2 Europe Biosimilars Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilars Treatment Market Size by Country (2019-2024)
7.4 Europe Biosimilars Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars Treatment Market Size (2019-2030)
8.2 Asia-Pacific Biosimilars Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilars Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilars Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilars Treatment Market Size (2019-2030)
9.2 Latin America Biosimilars Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilars Treatment Market Size by Country (2019-2024)
9.4 Latin America Biosimilars Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars Treatment Market Size (2019-2030)
10.2 Middle East & Africa Biosimilars Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilars Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilars Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Biosimilars Treatment Introduction
11.1.4 Bayer Revenue in Biosimilars Treatment Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 Eli Lily, Inc.
11.2.1 Eli Lily, Inc. Company Detail
11.2.2 Eli Lily, Inc. Business Overview
11.2.3 Eli Lily, Inc. Biosimilars Treatment Introduction
11.2.4 Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2019-2024)
11.2.5 Eli Lily, Inc. Recent Development
11.3 Pfizer, Inc.
11.3.1 Pfizer, Inc. Company Detail
11.3.2 Pfizer, Inc. Business Overview
11.3.3 Pfizer, Inc. Biosimilars Treatment Introduction
11.3.4 Pfizer, Inc. Revenue in Biosimilars Treatment Business (2019-2024)
11.3.5 Pfizer, Inc. Recent Development
11.4 Sandoz International GmbH
11.4.1 Sandoz International GmbH Company Detail
11.4.2 Sandoz International GmbH Business Overview
11.4.3 Sandoz International GmbH Biosimilars Treatment Introduction
11.4.4 Sandoz International GmbH Revenue in Biosimilars Treatment Business (2019-2024)
11.4.5 Sandoz International GmbH Recent Development
11.5 Teva Pharmaceutical Industries Limited
11.5.1 Teva Pharmaceutical Industries Limited Company Detail
11.5.2 Teva Pharmaceutical Industries Limited Business Overview
11.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2019-2024)
11.5.5 Teva Pharmaceutical Industries Limited Recent Development
11.6 Amgen Inc.
11.6.1 Amgen Inc. Company Detail
11.6.2 Amgen Inc. Business Overview
11.6.3 Amgen Inc. Biosimilars Treatment Introduction
11.6.4 Amgen Inc. Revenue in Biosimilars Treatment Business (2019-2024)
11.6.5 Amgen Inc. Recent Development
11.7 Biocon
11.7.1 Biocon Company Detail
11.7.2 Biocon Business Overview
11.7.3 Biocon Biosimilars Treatment Introduction
11.7.4 Biocon Revenue in Biosimilars Treatment Business (2019-2024)
11.7.5 Biocon Recent Development
11.8 Dr. Reddy’s Laboratories
11.8.1 Dr. Reddy’s Laboratories Company Detail
11.8.2 Dr. Reddy’s Laboratories Business Overview
11.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Introduction
11.8.4 Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2019-2024)
11.8.5 Dr. Reddy’s Laboratories Recent Development
11.9 Roche Ltd.
11.9.1 Roche Ltd. Company Detail
11.9.2 Roche Ltd. Business Overview
11.9.3 Roche Ltd. Biosimilars Treatment Introduction
11.9.4 Roche Ltd. Revenue in Biosimilars Treatment Business (2019-2024)
11.9.5 Roche Ltd. Recent Development
11.10 Celltrion, Inc.
11.10.1 Celltrion, Inc. Company Detail
11.10.2 Celltrion, Inc. Business Overview
11.10.3 Celltrion, Inc. Biosimilars Treatment Introduction
11.10.4 Celltrion, Inc. Revenue in Biosimilars Treatment Business (2019-2024)
11.10.5 Celltrion, Inc. Recent Development
11.11 Samsung Bioepis
11.11.1 Samsung Bioepis Company Detail
11.11.2 Samsung Bioepis Business Overview
11.11.3 Samsung Bioepis Biosimilars Treatment Introduction
11.11.4 Samsung Bioepis Revenue in Biosimilars Treatment Business (2019-2024)
11.11.5 Samsung Bioepis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
